We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Immunexpress Releases Key Performance Data on SeptiCyte®
News

Immunexpress Releases Key Performance Data on SeptiCyte®

Immunexpress Releases Key Performance Data on SeptiCyte®
News

Immunexpress Releases Key Performance Data on SeptiCyte®

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Immunexpress Releases Key Performance Data on SeptiCyte® "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

SeptiCyte®Lab is a rapid molecular assay that measures a patient’s gene expression level to differentiate between sepsis and infection-negative systemic inflammation.

The manuscript describes the identification of a classifier to accurately discriminate sepsis patients from patients with non-septic inflammation and the conversion of the classifier to RT-qPCR format which is the basis of the SeptiCyte® technology. The study details the validation of the technology across five independent patient cohorts and demonstrates clinical performance that outperforms clinical parameters including procalcitonin.

“Current technologies for the diagnosis of sepsis that seek to identify the causative pathogen are slow and frequently result in false negatives,” said Roslyn Brandon, President and CEO of Immunexpress. “Our technology, described today in PLOS Medicine, examines the host-response and can provide a probability of sepsis in 100% of cases just a few hours after a physician’s initial suspicion of sepsis. We look forward to sharing data from our prospective FDA regulatory trials of SeptiCyte® next year.”

Advertisement